We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




PET Scan May Help Personalize Cancer Treatment

By MedImaging International staff writers
Posted on 14 Mar 2018
Print article
Image: PET images of kidneys and spleen 90 minutes post injection of 18F-BMS-986192 and anti-PD-L1 immunohistochemistry of healthy monkey spleen tissue (R) (Photo courtesy of David Donnelly/ BMS).
Image: PET images of kidneys and spleen 90 minutes post injection of 18F-BMS-986192 and anti-PD-L1 immunohistochemistry of healthy monkey spleen tissue (R) (Photo courtesy of David Donnelly/ BMS).
A same-day, noninvasive positron emission tomography (PET)-based imaging approach could help guide cancer treatment decisions and assess treatment response, claims a new study.

Researchers at Bristol-Myers Squibb (BMS; Princeton, NJ, USA) have developed a fluorine-18 (18F)-labeled engineered protein that targets the programmed death protein (PD-1), and its ligand PD-L1, which enables cancer to evade the immune system. The PD-L1 radioligand (18F-BMS-986192) was then evaluated in mice bearing bilateral PD-L1(-) and PD-L1(+) subcutaneous tumors in human tissues, as well as evaluating distribution, binding and radiation dosimetry in healthy cynomolgus monkey.

The results revealed that 18F-BMS-986192 bound to human and cynomolgus PD-L1 tumor tissues as a function of PD-L1 expression, with radioligand binding blocked in a dose-dependent manner. In-vivo PET imaging clearly visualized PD-L1 expression in the mice implanted with PD-L1(+) xenograft tumors. Two hours after dosing, a 3.5-fold-higher uptake was observed in the implanted mice, compared to control mice with PD-L1(–) tumors. Co-administration of an anti–PD-L1 adnectin reduced tumor uptake at two hours after injection by approximately 70%, demonstrating PD-L1–specific binding.

Biodistribution in the cynomolgus monkey showed binding in the spleen, which is rich in the PD-L1, with rapid blood clearance through the kidneys and bladder. Binding in the PD-L1(+) spleen was also reduced by co-administration of 18F-BMS-986192. According to the researchers, the results demonstrate the feasibility of the approach, and that radiation dosimetry estimates indicate that the tracer is safe to administer in human studies. The study was published in the March 2018 issue of The Journal of Nuclear Medicine.

“This approach represents an opportunity for physicians to noninvasively assess all of a patient's tumors for PD-L1 expression with a single PET scan and timely readout,” said lead author David Donnelly, PhD, of BMS Pharmaceutical Research and Development. “This may help guide treatment decisions and assess treatment response, to help identify the right treatment for the right patient at the right time and right dose.”

The PD-1 pathway is a cell surface receptor that plays an important role in down-regulating the immune system and promoting self-tolerance by suppressing T-cell inflammatory activity. The pathway guards against autoimmunity through a dual mechanism of promoting apoptosis in lymph node antigen-specific T-cells, while simultaneously reducing apoptosis in regulatory T-cells. Through these mechanisms, PD-1 inhibits the immune system, preventing autoimmune diseases, but it can also prevent the immune system from killing cancer cells.

Related Links:
Bristol-Myers Squibb

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Advanced Cardiac MRI Analysis Software
3Di Cardiac MR
New
Ultrasound Software
UltraExtend NX
New
C-Arm with FPD
Digiscan V20 / V30

Print article

Channels

Ultrasound

view channel
Image: Structure of the proposed transparent ultrasound transducer and its optical transmittance (Photo courtesy of POSTECH)

Ultrasensitive Broadband Transparent Ultrasound Transducer Enhances Medical Diagnosis

The ultrasound-photoacoustic dual-modal imaging system combines molecular imaging contrast with ultrasound imaging. It can display molecular and structural details inside the body in real time without... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The acquisition will expand IBA’s medical imaging quality assurance offering (Photo courtesy of Radcal)

IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering

Ion Beam Applications S.A. (IBA, Louvain-La-Neuve, Belgium), the global leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, has entered... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.